← All thesesHIMSUnattractiveHigh convictionTuesday 17 November 2026עברית

Hims & Hers Health

This is the archived full research. Read the story

An online clinic: customers see a doctor in an app and get treatments for weight, hair, skin and more mailed to them every month.

Our viewUnattractive High conviction
The scores
The profile · 1-4
Growth3/4 ↓

Revenue grew from $148.8M in 2020 to $2.35B in 2025 and 49% in Q3 2026, but US revenue grew 21%; the rest was mostly bought.

Business quality2/4 ↓

Revenue per subscriber rose to $105, but makers sell the same drugs at the same prices, customers cancel monthly, and gross margin fell to 57%.

Financial position2/4 ↓

$712.2M of cash against $1.37B of notes, $563.1M owed for Eucalyptus and a working capital deficit, though operating cash flow stays positive.

Execution record2/4 ↓

Missed the analysts' earnings estimate in each of the last three reports, took $70M of charges on the weight-loss shift and guides a lower margin.

Per share capture3/4 →

Revenue per share rose 38.0% in a year, but acquisition payments and notes may become shares and no stock was bought back this year.

Potential3/4 →

One in eight US adults take a GLP-1 drug and a sixth buy online, but the dollars the platform can keep are unmeasured.

Risk profile2/4 ↓

An FTC suit, drug makers that are both suppliers and rivals, compounding rules and a controlling founder with 87.73% of the votes.

Valuation1/4 ↑

About 1.94 times trailing sales with an operating loss, 439% of an early-stage value near $4.23 and above the bull case: priced for perfection.

Evidence quality3/4 →

Revenue, margins, cash and obligations are filed; specialty sizes, the AI experience and run-rates are management's word, and no churn rate is disclosed.

The bet · 2-3 years
Priced for success0.9×

If it works 0.9× · if it fails you keep about 73%.

The Verdict

We rate Hims & Hers Unattractive. Revenue grew 49% in Q3 2026, but much of that came from clinics it bought abroad. At home it now sells branded weight-loss drugs at the prices their makers charge anyone, so it keeps less of each sale: the gross margin fell from 74% to 57% and profit turned to a loss. Its best year earned 4.5% of sales, and it owes more than it holds in cash. On that, the price is about 439% of our value of about $4.23, above even our best case. As a bet on its newer treatments it is priced for success.

The long caseIf subscribers already on the app add testosterone, peptides or blood tests, each pays more without the company paying again to find them.

How we weighed it

The price against our value

Against it

Price at 439% of our value

The price sits far above our value and above our bull case.

The business

Against it

Mixed

The brands draw customers, but the drugs are the makers' at the makers' prices and customers cancel monthly.

Growth against what the price assumes

Cuts both ways

Revenue grows fast, but at home it has slowed and much of the rest was bought abroad.

What could go wrong

Against it

A government suit over subscriptions, compounding rules, suppliers that compete with it and a founder who controls the votes.

Against competitors

Against it

The drug makers offer their drugs directly, and private apps and Amazon offer the same care.

How its group is behaving

Cuts both ways

It moves with the weight-loss drug trade, which grows fast but is set by two makers.

The latest news and report

Cuts both ways

The Lilly deal widens the shelf, but the last report cut the margin guide and subscribers fell.

The evidence under this - 7 claims
C28inferencemedium confidence
Valued on the early-stage method at an 8% required return, Hims & Hers is worth about $4.23 a share in the base case, $1.41 in the bear and $16.05 in the bull, so $18.56 is about 439% of the base: the analysts' revenue path for three years, then fading to 4%, and a normal margin of 4.5%, its best filed year.
derivedC26 for the analysts' path, C02 and C11 for the margins, C10 for stock pay, C12 and C15 for the bridge and shares.
against this

A normal margin of 10%, twice the best year, still gives about $16 a share, below the price.

current state · 2026-11-16written 2026-11-17
C27inferencemedium confidence
At $18.56 the company value is about $5.56B on 233.8M diluted shares plus $1.93B of notes and the Eucalyptus payable less $0.71B of cash, about 1.9 times trailing sales of $2,869.5M; with an operating loss there is no profit multiple.
derivedC12, C15 and C24 for cash, obligations, shares and price; C03 and C02 with the 10-Q for trailing revenue.
against this

Counting the earn-outs of $170.8M adds about 0.06 times sales; leaving out the Eucalyptus payable, which may be paid in shares, lowers it by 0.2.

current state · 2026-11-16written 2026-11-17
C08facthigh confidence
Under a November 2026 agreement Lilly's Zepbound and Foundayo reach Hims & Hers patients at Lilly's own self-pay prices, from $149 a month for Foundayo and $299 for Zepbound, and Hims & Hers committed never to offer compounded copies of Lilly's drugs.
current state · 2026-11-06written 2026-11-17
C02facthigh confidence
Revenue was $2,347.6M in 2025, up 59% from $1,476.5M, after $148.8M in 2020; GAAP operating income was $61.9M in 2024 and $105.6M in 2025, 4.2% and 4.5% of revenue, its only two profitable years.
historical · FY2020-FY2025written 2026-11-17
C05facthigh confidence
The gross margin was 57% in the quarter to September 2026 against 74% a year earlier; the GAAP operating loss was $66.1M and the net loss $33.0M, against net income of $15.8M.
historical · Q3 2026written 2026-11-17
C03facthigh confidence
In the quarter to September 2026 revenue was $890.4M, up 49%: United States revenue $657.1M, up 21%, and the rest of the world $233.3M, more than four times a year earlier, about $135M of it from Eucalyptus.
historical · Q3 2026written 2026-11-17
C12facthigh confidence
At 30 September 2026 Hims & Hers held $605.6M of cash and $106.6M of short-term investments against $1,367.4M of convertible notes, $563.1M owed for Eucalyptus and $170.8M of earn-outs; it had a working capital deficit of $114.8M.
current state · 2026-09-30written 2026-11-17
01

The company

Hims & Hers lets people get treatment for things they would rather not raise with a family doctor, or that insurance will not pay for: hair loss, erectile problems, weight, skin, menopause, low testosterone. A customer answers questions in the app, a licensed doctor or nurse writes a prescription, and the company's own pharmacies mail it.

About 2.79 million people subscribe. Without it they would see their own doctor, buy from the drug maker's website, or use a rival app such as LifeMD or the private Ro.

The evidence under this - 5 claims
C01facthigh confidence
Hims & Hers runs an online platform where customers see licensed providers, get prescriptions and receive treatments by mail, mostly on automatic subscriptions, in weight loss, sexual health, hair loss, dermatology, mental health, menopause and testosterone, under the Hims and Hers brands.
current state · 2025-12-31written 2026-11-17
C04facthigh confidence
Subscribers were 2,788 thousand at September 2026, up 13% from 2,471 thousand, and monthly revenue per average subscriber was $105, up from $81.
against this

Management expects another quarter of subscriber headwinds in the fourth quarter (C09).

current state · 2026-09-30written 2026-11-17
C16facthigh confidence
The 10-K says no direct competitor offers the full suite, and names classes rather than companies: providers, pharmacies and retailers, smaller online clinics, private compounders, drug makers selling direct, and employer telehealth.
current state · 2025-12-31written 2026-11-17
C17facthigh confidence
LifeMD, a listed rival, describes itself in its own 10-K as a direct-to-patient telehealth company, selling online care and prescriptions to the same consumers.
current state · 2025-12-31written 2026-11-17
C38facthigh confidence
Hims & Hers had 2,442 employees and about 1,586 affiliated providers at the end of 2025, and runs more than 1 million square feet of its own pharmacies, labs and compounding sites.
current state · 2025-12-31written 2026-11-17

How it makes money

Customers are billed automatically every month until they cancel or pause, and each paid about $105 a month in Q3 2026, up from $81 a year earlier as more bought weight-loss drugs. About three quarters of revenue comes from the United States and a quarter from clinics abroad. No one customer matters much.

The evidence under this - 4 claims
C04facthigh confidence
Subscribers were 2,788 thousand at September 2026, up 13% from 2,471 thousand, and monthly revenue per average subscriber was $105, up from $81.
against this

Management expects another quarter of subscriber headwinds in the fourth quarter (C09).

current state · 2026-09-30written 2026-11-17
C35facthigh confidence
Subscribers can cancel or pause between billing periods, as the release's definition says, and the 10-K warns that drug makers, retailers and technology companies with far larger resources compete for the same customers.
current state · 2026-09-30written 2026-11-17
C03facthigh confidence
In the quarter to September 2026 revenue was $890.4M, up 49%: United States revenue $657.1M, up 21%, and the rest of the world $233.3M, more than four times a year earlier, about $135M of it from Eucalyptus.
historical · Q3 2026written 2026-11-17
C40facthigh confidence
Revenue from the rest of the world was $233.3M in the quarter to September 2026, about a quarter of the total, against $55.5M a year earlier.
historical · Q3 2026written 2026-11-17
Where the money comes from, stream by stream
StreamShare of sales (Q3 2026)How it earns it
United States74%Subscriptions to online care and treatments under the Hims and Hers brands, from weight loss to hair, skin and sexual health.
Rest of the world26%Online clinics bought in Britain, Europe, Australia and Canada: Zava, Eucalyptus and Medici.

Who runs it

Andrew Dudum co-founded the company and has run it since it listed in 2021. Through special shares with 175 votes each he controls about 88% of the votes, so outside shareholders cannot outvote him.

His long-term pay rests on 2027 revenue and management's own profit measure, which leaves out stock pay.

The evidence under this - 3 claims
C29facthigh confidence
Andrew Dudum co-founded the company and has been chief executive and chairman since it listed in January 2021; through Class V shares with 175 votes each he holds 87.73% of the voting power, so Hims & Hers is a controlled company.
current state · 2026-04-28written 2026-11-17
C30facthigh confidence
Directors and officers own 8.44% of the Class A shares and 87.93% of the votes; BlackRock owns 10.35% of the Class A shares.
current state · 2026-04-28written 2026-11-17
C31facthigh confidence
The chief executive's 2025 performance options vest on 2027 revenue and adjusted EBITDA targets, 557,244 at target and up to 250% of that; other officers' awards vest with time.
current state · 2026-04-28written 2026-11-17
02

Why it wins, and who could beat it

Why customers come back

Its edge is its two brands and one app for many conditions: someone who came for hair loss can add skin or weight care without searching again. Each subscriber pays more than a year ago, and marketing fell to 28% of revenue.

The weak spot is that the drugs are not its own. Lilly sells the same weight-loss drugs to any patient at the same prices, and a customer can cancel any month.

The evidence under this - 5 claims
C04facthigh confidence
Subscribers were 2,788 thousand at September 2026, up 13% from 2,471 thousand, and monthly revenue per average subscriber was $105, up from $81.
against this

Management expects another quarter of subscriber headwinds in the fourth quarter (C09).

current state · 2026-09-30written 2026-11-17
C22management claimmedium confidence
Management says its AI-native experience reached 70% of weight-loss subscribers at September and marketing fell to 28% of revenue in the quarter, 7 points lower than in the second quarter.
against this

Management paced marketing on purpose and expects subscriber headwinds to follow, so the lower share may not hold (C09).

current state · 2026-09-30written 2026-11-17
C08facthigh confidence
Under a November 2026 agreement Lilly's Zepbound and Foundayo reach Hims & Hers patients at Lilly's own self-pay prices, from $149 a month for Foundayo and $299 for Zepbound, and Hims & Hers committed never to offer compounded copies of Lilly's drugs.
current state · 2026-11-06written 2026-11-17
C19factmedium confidence
KFF found about one in eight US adults, 12%, currently taking a GLP-1 drug in late 2025; about 17% of users got it from an online provider, and 27% of insured users paid the full cost themselves.
against this

A survey of self-reported use; it does not measure spending.

current state · 2025-11-02written 2026-11-17
C35facthigh confidence
Subscribers can cancel or pause between billing periods, as the release's definition says, and the 10-K warns that drug makers, retailers and technology companies with far larger resources compete for the same customers.
current state · 2026-09-30written 2026-11-17

The threat

Lilly and Novo Nordisk, which make the weight-loss drugs, sell them to patients directly. Rival apps such as LifeMD and the private Ro offer the same care, and Amazon runs its own online clinic and pharmacy. A family doctor with insurance is still how most people get these drugs.

The evidence under this - 4 claims
C08facthigh confidence
Under a November 2026 agreement Lilly's Zepbound and Foundayo reach Hims & Hers patients at Lilly's own self-pay prices, from $149 a month for Foundayo and $299 for Zepbound, and Hims & Hers committed never to offer compounded copies of Lilly's drugs.
current state · 2026-11-06written 2026-11-17
C07facthigh confidence
Novo Nordisk sued Hims & Hers over a semaglutide patent on 9 February 2026 and dismissed the suit without prejudice on 9 March 2026; the platform now offers Novo's Wegovy pen and pill.
against this

A dismissal without prejudice lets Novo sue again.

historical · February to November 2026written 2026-11-17
C17facthigh confidence
LifeMD, a listed rival, describes itself in its own 10-K as a direct-to-patient telehealth company, selling online care and prescriptions to the same consumers.
current state · 2025-12-31written 2026-11-17
C16facthigh confidence
The 10-K says no direct competitor offers the full suite, and names classes rather than companies: providers, pharmacies and retailers, smaller online clinics, private compounders, drug makers selling direct, and employer telehealth.
current state · 2025-12-31written 2026-11-17

The rivals: LLY, NVO, LFMD, AMZN, and 4 more that are private, in-house or listed abroad.

Who else does this, rival by rival
TickerRivalWhere it competesHow far alongPriced against it
LLYLillyDirect, Lilly's own self-pay channelPriced against it: One segment onlyUS telehealth platform: weight loss, sexual health, hair, skin, menopause and mental healthOn saleOne segment only
NVONovoCare, Novo Nordisk's own self-pay channelPriced against it: One segment onlyUS telehealth platform: weight loss, sexual health, hair, skin, menopause and mental healthOn saleOne segment only
LFMDLifeMD's direct-to-patient telehealthPriced against it: Same productUS telehealth platform: weight loss, sexual health, hair, skin, menopause and mental healthOn saleSame product
PrivateRo and other private online clinicsPriced against it: PrivateUS telehealth platform: weight loss, sexual health, hair, skin, menopause and mental healthOn salePrivate
AMZNAmazon One Medical and Amazon PharmacyPriced against it: One segment onlyUS telehealth platform: weight loss, sexual health, hair, skin, menopause and mental healthOn saleOne segment only
Not listedFamily doctors and retail pharmaciesPriced against it: Not listedUS telehealth platform: weight loss, sexual health, hair, skin, menopause and mental healthOn saleNot listed
PrivateLocal online clinics in each countryPriced against it: PrivateInternational platform: Zava, Eucalyptus and MediciOn salePrivate
PrivateCompounding pharmacies and medical spas selling peptides and testosteronePriced against it: PrivateNewer lines: testosterone, peptides and lab testingOn salePrivate
03

How big it could get

How big this could get

About one in eight American adults were taking a weight-loss or diabetes drug of this kind in late 2025, and about a sixth of them got it online. Hims & Hers' whole US business took in $2.2B in 2025.

Nobody outside publishes how much people spend on these drugs online, so the size of the market it sells into is not measured in dollars.

The evidence under this - 3 claims
C19factmedium confidence
KFF found about one in eight US adults, 12%, currently taking a GLP-1 drug in late 2025; about 17% of users got it from an online provider, and 27% of insured users paid the full cost themselves.
against this

A survey of self-reported use; it does not measure spending.

current state · 2025-11-02written 2026-11-17
C02facthigh confidence
Revenue was $2,347.6M in 2025, up 59% from $1,476.5M, after $148.8M in 2020; GAAP operating income was $61.9M in 2024 and $105.6M in 2025, 4.2% and 4.5% of revenue, its only two profitable years.
historical · FY2020-FY2025written 2026-11-17
C03facthigh confidence
In the quarter to September 2026 revenue was $890.4M, up 49%: United States revenue $657.1M, up 21%, and the rest of the world $233.3M, more than four times a year earlier, about $135M of it from Eucalyptus.
historical · Q3 2026written 2026-11-17
04

The results

The numbers

Is it growing?Fast

Sales grew 30% over the twelve months to Sep 2026, slower than the 59% in the year to Dec 2025.

Dec 2021: $272MDec 2022: $527MDec 2023: $872MDec 2024: $1.48BDec 2025: $2.35B12 mo to Sep 2026: $2.87B$272M$2.87B
Is it profitable?Losing

Operating margin is −8.1%, down from −3.4% in the year to Dec 2023.

Dec 2021: −42%Dec 2022: −13%Dec 2023: −3.4%Dec 2024: 4.2%Dec 2025: 4.5%12 mo to Sep 2026: −8.1%−42%−8.1%
Does growth pay off?Costly

Running costs take 72¢ of each sales dollar, down from 118¢ in the year to Dec 2021.

Dec 2021: 118¢Dec 2022: 91¢Dec 2023: 85¢Dec 2024: 75¢Dec 2025: 69¢12 mo to Sep 2026: 72¢118¢72¢
Does it earn good returns?Poor

Shareholders' money lost 41% a year, up from −115% in the year to Dec 2021.

Dec 2021: −115%Dec 2022: −20%Dec 2023: −7.2%Dec 2024: 31%Dec 2025: 25%12 mo to Sep 2026: −41%−115%−41%
Is it making cash?Thin

It turned 0.3% of sales into free cash, $8.22M over the last twelve months.

Dec 2022: −$33.7MDec 2023: $47.0MDec 2024: $198MDec 2025: $57.4M12 mo to Sep 2026: $8.22M−$33.7M$8.22M
Is the balance sheet safe?Heavy debt

It owes $655M more than the cash it holds, about 3.6 years of the cash its operations bring in.

Dec 2024: $300MDec 2025: −$395M12 mo to Sep 2026: −$655M$300M−$655M
Are shares being diluted?Diluting

The share count rose 25% in 4.8 years, and pay in shares costs 6.2% of sales.

Dec 2021: 187MDec 2022: 205MDec 2023: 209MDec 2024: 237MDec 2025: 258M12 mo to Sep 2026: 234M187M234M
All the numbers

Filed figures from the company's 10-K and 10-Q, read 2026-11-17. Fiscal years end in December.

Dec 2021Dec 2022Dec 2023Dec 2024Dec 202512 mo to Sep 2026
Size and growth
Sales$272M$527M$872M$1.48B$2.35B$2.87B
Sales growth+83%+94%+65%+69%+59%+30%
Profit
Gross margin75%78%82%79%74%64%
Operating margin−42%−13%−3.4%4.2%4.5%−8.1%
Net margin−40%−12%−2.7%8.5%5.5%−6.7%
What growth costs, per sales dollar
Sales and marketing50%52%51%46%39%34%
General and admin42%19%15%11%12%18%
Pay in shares25%8.1%7.6%6.3%5.8%6.2%
Capital spending-1.4%3.0%3.6%10%6.0%
Cash
Cash from operations−$34.4M−$26.5M$73.5M$251M$300M$180M
Free cash flow-−$33.7M$47.0M$198M$57.4M$8.22M
Balance sheet
Cash and short-term investments$247M$180M$221M$300M$577M$712M
Debt---$0$973M$1.37B
Net cash---$300M−$395M−$655M
Returns and shares
Return on capital---15%11%-
Shares (diluted)187M205M209M237M258M234M

What growth costs

Until 2025 growth made the company more profitable: marketing and admin fell as a share of sales and official profit turned positive. Since then branded drugs and bought clinics have cut what it keeps from each sale, and over the past year it lost about 8 cents on each dollar.

The evidence under this - 3 claims
C32facthigh confidence
From 2022 to 2025 selling and marketing fell from 51.7% to 39.2% of revenue and admin from 18.6% to 11.6%, while the gross margin fell from 77.6% to 73.8% and capital spending rose from $7.2M to $242.6M.
historical · FY2022-FY2025written 2026-11-17
C11facthigh confidence
Over the four quarters to September 2026 the gross margin was 63.8%, from 79.5% in 2024, the GAAP operating margin minus 8.1%, and selling and marketing 33.8% of revenue, from 46.0% in 2024.
historical · FY2024 to the four quarters to September 2026written 2026-11-17
C02facthigh confidence
Revenue was $2,347.6M in 2025, up 59% from $1,476.5M, after $148.8M in 2020; GAAP operating income was $61.9M in 2024 and $105.6M in 2025, 4.2% and 4.5% of revenue, its only two profitable years.
historical · FY2020-FY2025written 2026-11-17

The last report (9 Nov)

Quarter ended September 2026, filed figures.

49%
Sales growth
against the same quarter a year earlier
18.2%
Growth from the quarter before
against 23.9% the quarter before that
-7¢
Operating profit
per dollar of sales

In Q3 2026, the quarter to September, revenue rose 49% to $890.4M, but US revenue rose 21% and about $135M came from Eucalyptus, bought in June. Subscribers rose 13% from a year earlier to 2.79 million.

The gross margin fell to 57% from 74% as branded drugs replaced the company's own, and it lost $33.0M. Management expects another quarter of fewer subscribers and guides a lower margin for the year.

What it did to the thesisIt weakened the business case: growth at home slowed, the margin fell sharply on branded drugs, and subscribers are expected to fall again. Revenue per subscriber rose, which helps, but nothing in it closes the gap between the price and our value.

The quarter in detail

Sales growth from the previous quarter, filed figures.

Earnings per share $-0.14 against $0.06 expected; $-0.14 as filed, with no adjustments.

The evidence under this - 5 claims
C03facthigh confidence
In the quarter to September 2026 revenue was $890.4M, up 49%: United States revenue $657.1M, up 21%, and the rest of the world $233.3M, more than four times a year earlier, about $135M of it from Eucalyptus.
historical · Q3 2026written 2026-11-17
C04facthigh confidence
Subscribers were 2,788 thousand at September 2026, up 13% from 2,471 thousand, and monthly revenue per average subscriber was $105, up from $81.
against this

Management expects another quarter of subscriber headwinds in the fourth quarter (C09).

current state · 2026-09-30written 2026-11-17
C05facthigh confidence
The gross margin was 57% in the quarter to September 2026 against 74% a year earlier; the GAAP operating loss was $66.1M and the net loss $33.0M, against net income of $15.8M.
historical · Q3 2026written 2026-11-17
C09management claimhigh confidence
Management guides 2026 revenue of $3.13B to $3.15B, up 33% to 34%, and adjusted EBITDA of $257M to $277M, 8% to 9% of revenue, and expects another quarter of subscriber headwinds while it paces marketing.
against this

Adjusted EBITDA was 13.5% of revenue in 2025 (C10), so the guide is a lower margin.

forwardwritten 2026-11-17
C40facthigh confidence
Revenue from the rest of the world was $233.3M in the quarter to September 2026, about a quarter of the total, against $55.5M a year earlier.
historical · Q3 2026written 2026-11-17
What management did with the money

Insiders in 2026Q3: 30 purchases and 61 sales, from their Form 4 filings.

05

The price, and where we disagree

In short. Priced for perfection. The price is about 439% of what we think the business is worth at an 8% yearly return, and above our best case.

Share price
$18.56
close,
Company value for each $1 of sales
1.8
its 6-year normal 3.3

The shares fell 48.5% in a year while revenue per share rose 38%, so buyers now pay far less for each dollar of sales. Lilly's drugs join the app this quarter.

The next test is the fourth-quarter report, expected on 22 February 2027: whether subscribers grow again with both makers' drugs on offer, and what profit margin management guides for 2027.

The evidence under this - 4 claims
C24facthigh confidence
The shares closed at $18.56 on 16 November 2026, down 48.5% in a year while revenue per share rose 38.0%, so the multiple of sales fell by about 63%; the year's range was $13.74 to $40.99.
current state · 2026-11-16written 2026-11-17
C09management claimhigh confidence
Management guides 2026 revenue of $3.13B to $3.15B, up 33% to 34%, and adjusted EBITDA of $257M to $277M, 8% to 9% of revenue, and expects another quarter of subscriber headwinds while it paces marketing.
against this

Adjusted EBITDA was 13.5% of revenue in 2025 (C10), so the guide is a lower margin.

forwardwritten 2026-11-17
C08facthigh confidence
Under a November 2026 agreement Lilly's Zepbound and Foundayo reach Hims & Hers patients at Lilly's own self-pay prices, from $149 a month for Foundayo and $299 for Zepbound, and Hims & Hers committed never to offer compounded copies of Lilly's drugs.
current state · 2026-11-06written 2026-11-17
C18facthigh confidence
The FTC, with Utah and Los Angeles County, sued Hims & Hers in July 2026 over its subscription, cancellation and privacy practices; its motion to dismiss is set for 14 January 2027, and it accrued $62.5M for legal contingencies.
against this

The company says the claims are without merit and has moved to dismiss.

current state · 2026-09-30written 2026-11-17
The betPriced for success
If it works
0.9×
from today's value, at the stated multiple
If it fails
keep 73%
of today's market value: the rest of the company, less its debt
How we value it
Method
Cash the business will produce, with any shortfall raised in new shares
Required return
8%
Long-run growth
4%
Moat
No moat
BearBaseBull
Sales growth, years 1 to 314.4%, 8.1%, 5.9%28.9%, 16.2%, 11.9%36.1%, 20.3%, 14.9%
Normal operating margin2.3%4.5%10%
Return on new capital after year ten8%8%11%
Value a share$1.41$4.23$16.05
Price
$18.56
Priced on
16 Nov
Price as a share of the base value
439%
Yearly return the price offers on the base case
5.2%
Risk check: valued at 12%, the rate for a business not yet making a profit
$2.00

Where each figure comes from

FigureSourceWhere exactly
Sales, the last twelve monthsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date.
Operating margin todayFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the four quarters to that date.
Tax rateOur method's ruleThe normal rate where no rate is filed to read: 25% for a US company, 21% elsewhere.
Sales per dollar of new capitalOur method's ruleOur default of 2, since the filings give no operating capital to read.
SharesFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the diluted share count.
Cash and investmentsFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the balance sheet on that date.
DebtFiled reportQuarterly report (10-Q) for the period to 30 Sep 2026, filed 9 Nov 2026; the balance sheet on that date.
Sales growth, years 1 to 3Analysts' forecastsFMP's consensus for the years to 31 Dec 2026, 31 Dec 2027, 31 Dec 2028 and 31 Dec 2029: the average of 5 to 11 analysts' revenue estimates, 28.9%, 16.2%, 11.9%. FMP publishes how many analysts, not who they are.
Normal operating marginOur judgementOur reading of the evidence; each case below names it.
Return on new capital after year tenOur method's ruleSet by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate.
The bear and bull casesOur method's ruleOur method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin.
PriceMarket priceFMP's closing price on 16 Nov 2026.

What each case rests on

Bear caseGrowth runs at half the analysts' path, 14%, 8% and 6%, the margin settles at 2.3%, the analysts' 2028 operating margin of 8.5% less stock pay near 6.2%, and new capital earns only the 8% rate: the test of a price war with the drug makers.

Base caseRevenue grows 29%, 16% and 12% over three years, the analysts' path (C26), then fades toward 4%, closing 30% of the gap each year; the margin moves from minus 8.1% to 4.5%, the best year it has filed (2025), with stock pay near 6% a cost and new capital earning only the 8% rate.

Bull caseGrowth runs a quarter above the analysts' path, 36%, 20% and 15%, the margin reaches 10%, more than twice its best filed year of 4.5%, and new capital earns 11%: the test of scale cutting marketing and pharmacy costs.

What moves the base value

LowerHigher
Growth in years 1 to 3, a quarter lower or higher$3.83$4.65
The normal margin, 15% lower or higher$3.44$5.05
Capital per dollar of growth, a quarter more or less$3.82$4.55
Return on new capital after year ten, at the rate or one step up$4.23$5.48
The rate, a point higher or lower$3.08$6.14
Long-run growth a point lower$4.17-

Value a share as growth and margin change

Normal margin ↓ · growth →50%75%100%125%150%
3.6%$2.58$2.87$3.19$3.53$3.88
4%$3.01$3.33$3.70$4.08$4.48
4.5%$3.45$3.83$4.23$4.65$5.10
5%$3.89$4.33$4.77$5.24$5.73
5.4%$4.34$4.83$5.34$5.85$6.39

Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.

How we read the multiple

We count stock pay as a cost and the money still owed for Eucalyptus as debt.

  1. The whole company, with its notes and the money owed for Eucalyptus added and cash taken off, is worth about $5.56B.
  2. Sales over the past year were about $2.87B, and official operating profit was a loss of about 8% of that.
  3. That puts the price at about 1.9 times sales.
  4. Even if the analysts' sales path comes true and the margin returns to its best year, we value it at about $4.23 a share.

Against its own history. Buyers pay far less for each dollar of its sales than a year ago, when its own weight-loss drugs earned more; the fall prices in part of that.

The evidence under this - 5 claims
C28inferencemedium confidence
Valued on the early-stage method at an 8% required return, Hims & Hers is worth about $4.23 a share in the base case, $1.41 in the bear and $16.05 in the bull, so $18.56 is about 439% of the base: the analysts' revenue path for three years, then fading to 4%, and a normal margin of 4.5%, its best filed year.
derivedC26 for the analysts' path, C02 and C11 for the margins, C10 for stock pay, C12 and C15 for the bridge and shares.
against this

A normal margin of 10%, twice the best year, still gives about $16 a share, below the price.

current state · 2026-11-16written 2026-11-17
C27inferencemedium confidence
At $18.56 the company value is about $5.56B on 233.8M diluted shares plus $1.93B of notes and the Eucalyptus payable less $0.71B of cash, about 1.9 times trailing sales of $2,869.5M; with an operating loss there is no profit multiple.
derivedC12, C15 and C24 for cash, obligations, shares and price; C03 and C02 with the 10-Q for trailing revenue.
against this

Counting the earn-outs of $170.8M adds about 0.06 times sales; leaving out the Eucalyptus payable, which may be paid in shares, lowers it by 0.2.

current state · 2026-11-16written 2026-11-17
C10facthigh confidence
Adjusted EBITDA was $318.0M in 2025, 13.5% of revenue; stock pay was $135.2M in 2025, 5.8% of revenue, and $177.9M over the four quarters to September 2026, 6.2%.
historical · FY2025 and the four quarters to September 2026written 2026-11-17
C12facthigh confidence
At 30 September 2026 Hims & Hers held $605.6M of cash and $106.6M of short-term investments against $1,367.4M of convertible notes, $563.1M owed for Eucalyptus and $170.8M of earn-outs; it had a working capital deficit of $114.8M.
current state · 2026-09-30written 2026-11-17
C26estimatemedium confidence
Analysts expect revenue of $3,158M for 2026, $3,902M for 2027, $4,443M for 2028 and $4,943M for 2029, with operating profit on their basis of $424M by 2029, about 8.6%.
against this

Only five analysts forecast 2029, and the 2030 average falls to $4,720M.

forwardwritten 2026-11-17
Priced against its rivals

Only LifeMD sells the same thing to the same buyers as a large part of what it does. A price comparison needs at least two, so the price is judged against its own history instead.

Also checked and set aside: Teladoc Health (a substitute, not the same product).

Private or foreign rivals that cannot be priced: Ro (Roman Health Ventures), Compounding pharmacies and small online clinics.

The bet: what it pays if it works

This bet is on Hims & Hers' newer treatments: testosterone injections launched in October 2026, peptides launching in November and at-home blood tests. No revenue is filed for them.

Valued alone at what we think it deserves, the established platform covers less than today's price once the money owed is taken off, so part of the price already rests on the newer lines. If they reach the big win the shares gain little; if they fail, a lot is lost, which makes it a bet priced for success.

Newer lines: testosterone, peptides and lab testing revenue in two to three yearsSubscribers on newer treatments neededAt the stated multiple
$100.00Mabout 79.4K at 100% kept0.8×
$250.00M (the big win)about 198.4K at 100% kept0.9×
$500.00Mabout 396.8K at 100% kept1.0×

To pay 2× (a Fair bet) it would need about $3.09B of Newer lines: testosterone, peptides and lab testing revenue (about 2.5M subscribers on newer treatments); to pay 5× (a Cheap bet), about $10.66B of Newer lines: testosterone, peptides and lab testing revenue (about 8.5M subscribers on newer treatments), at the same multiple.

Each row is Newer lines: testosterone, peptides and lab testing alone, plus the rest of the company (Telehealth platform, US and abroad) counted at about $3.90B.

The steps it has to take

  • Done Testosterone injections launched
  • In progress Peptides offer launched due 2026-11
  • In progress Testosterone at a $100M annual run-rate due 2027-06
  • Not started Revenue from the newer lines disclosed due 2028-03
The detail behind the label
Rating
Expensive
the big win's payoff against the 2× and 5× lines
Cheap bet at about
≈ $0.14
99% below the price (close, )
The option
0.4×
what Newer lines: testosterone, peptides and lab testing is worth if it works, against what the price pays for it
The evidence under this - 5 claims
C21management claimmedium confidence
Testosterone injections launched in October 2026, the platform's first controlled substance, and a peptides offer launches in late November with no material revenue expected in the fourth quarter.
against this

Peptide compounding depends on rules the company says it will monitor.

current state · 2026-11-09written 2026-11-17
C20management claimmedium confidence
Management says Hers is progressing toward $1B of revenue this year, testosterone toward a $100M annual run-rate, and international toward a $1B run-rate in 2027.
against this

None of the three is a filed figure.

forwardwritten 2026-11-17
C26estimatemedium confidence
Analysts expect revenue of $3,158M for 2026, $3,902M for 2027, $4,443M for 2028 and $4,943M for 2029, with operating profit on their basis of $424M by 2029, about 8.6%.
against this

Only five analysts forecast 2029, and the 2030 average falls to $4,720M.

forwardwritten 2026-11-17
C27inferencemedium confidence
At $18.56 the company value is about $5.56B on 233.8M diluted shares plus $1.93B of notes and the Eucalyptus payable less $0.71B of cash, about 1.9 times trailing sales of $2,869.5M; with an operating loss there is no profit multiple.
derivedC12, C15 and C24 for cash, obligations, shares and price; C03 and C02 with the 10-Q for trailing revenue.
against this

Counting the earn-outs of $170.8M adds about 0.06 times sales; leaving out the Eucalyptus payable, which may be paid in shares, lowers it by 0.2.

current state · 2026-11-16written 2026-11-17
C12facthigh confidence
At 30 September 2026 Hims & Hers held $605.6M of cash and $106.6M of short-term investments against $1,367.4M of convertible notes, $563.1M owed for Eucalyptus and $170.8M of earn-outs; it had a working capital deficit of $114.8M.
current state · 2026-09-30written 2026-11-17

Where we disagree with the market

The market believes

A fast grower sold off too far: most analysts rate it a hold, a third a buy.

We believe

A busy online clinic that keeps little of each sale and owes more than it holds, priced above our best case.

Most analysts rate it a hold after the fall and value it on management's profit measure. Counting stock pay as a cost and the acquisition payments as debt, even twice its best margin leaves our value below the price.

The evidence against us: if scale cuts marketing and pharmacy costs and official profit passes 8% of sales while growth stays above 20%, the business could earn into today's price.

What analysts say, and the evidence
Analysts positive
20%
of 15, 1 Nov
Four months earlier
19%
of 16, 1 Jul
The evidence under this - 5 claims
C25facthigh confidence
Of 20 analysts, 7 rate the shares a buy, 13 a hold and none a sell; the positive share was 20.0% of 15 on FMP's series in November against 22.2% of 18 in March.
current state · 2026-11-01written 2026-11-17
C26estimatemedium confidence
Analysts expect revenue of $3,158M for 2026, $3,902M for 2027, $4,443M for 2028 and $4,943M for 2029, with operating profit on their basis of $424M by 2029, about 8.6%.
against this

Only five analysts forecast 2029, and the 2030 average falls to $4,720M.

forwardwritten 2026-11-17
C24facthigh confidence
The shares closed at $18.56 on 16 November 2026, down 48.5% in a year while revenue per share rose 38.0%, so the multiple of sales fell by about 63%; the year's range was $13.74 to $40.99.
current state · 2026-11-16written 2026-11-17
C28inferencemedium confidence
Valued on the early-stage method at an 8% required return, Hims & Hers is worth about $4.23 a share in the base case, $1.41 in the bear and $16.05 in the bull, so $18.56 is about 439% of the base: the analysts' revenue path for three years, then fading to 4%, and a normal margin of 4.5%, its best filed year.
derivedC26 for the analysts' path, C02 and C11 for the margins, C10 for stock pay, C12 and C15 for the bridge and shares.
against this

A normal margin of 10%, twice the best year, still gives about $16 a share, below the price.

current state · 2026-11-16written 2026-11-17
C02facthigh confidence
Revenue was $2,347.6M in 2025, up 59% from $1,476.5M, after $148.8M in 2020; GAAP operating income was $61.9M in 2024 and $105.6M in 2025, 4.2% and 4.5% of revenue, its only two profitable years.
historical · FY2020-FY2025written 2026-11-17
06

What could go wrong, and how we would know

The risks

  • Suppliers that compete. Lilly and Novo make the drugs and sell them to patients directly at identical prices.
  • A government lawsuit. The FTC is suing over how subscriptions renew and cancel; a hearing is set for January 2027.
  • Rules on what it sells. Compounding, online prescribing and controlled-substance rules govern testosterone, peptides and more.
  • Money owed. Notes and payments for Eucalyptus exceed its cash by about $1.2B, and some may be paid in new shares.
  • One person decides. The founder controls about 88% of the votes, so outside owners cannot overrule him.
The evidence under this - 6 claims
C08facthigh confidence
Under a November 2026 agreement Lilly's Zepbound and Foundayo reach Hims & Hers patients at Lilly's own self-pay prices, from $149 a month for Foundayo and $299 for Zepbound, and Hims & Hers committed never to offer compounded copies of Lilly's drugs.
current state · 2026-11-06written 2026-11-17
C07facthigh confidence
Novo Nordisk sued Hims & Hers over a semaglutide patent on 9 February 2026 and dismissed the suit without prejudice on 9 March 2026; the platform now offers Novo's Wegovy pen and pill.
against this

A dismissal without prejudice lets Novo sue again.

historical · February to November 2026written 2026-11-17
C18facthigh confidence
The FTC, with Utah and Los Angeles County, sued Hims & Hers in July 2026 over its subscription, cancellation and privacy practices; its motion to dismiss is set for 14 January 2027, and it accrued $62.5M for legal contingencies.
against this

The company says the claims are without merit and has moved to dismiss.

current state · 2026-09-30written 2026-11-17
C39facthigh confidence
Federal and state rules on compounding, telehealth prescribing and controlled substances govern much of what the platform sells, as the 10-K's regulation section and risk factors set out.
current state · 2025-12-31written 2026-11-17
C29facthigh confidence
Andrew Dudum co-founded the company and has been chief executive and chairman since it listed in January 2021; through Class V shares with 175 votes each he holds 87.73% of the voting power, so Hims & Hers is a controlled company.
current state · 2026-04-28written 2026-11-17
C12facthigh confidence
At 30 September 2026 Hims & Hers held $605.6M of cash and $106.6M of short-term investments against $1,367.4M of convertible notes, $563.1M owed for Eucalyptus and $170.8M of earn-outs; it had a working capital deficit of $114.8M.
current state · 2026-09-30written 2026-11-17
What we still do not know
  • How many subscribers cancel each month; the company does not say.
  • How much US weight loss earns now that it sells branded drugs, since no split by condition is filed.
  • Whether the FTC case forces changes to how the platform bills.
The evidence under this - 3 claims
C04facthigh confidence
Subscribers were 2,788 thousand at September 2026, up 13% from 2,471 thousand, and monthly revenue per average subscriber was $105, up from $81.
against this

Management expects another quarter of subscriber headwinds in the fourth quarter (C09).

current state · 2026-09-30written 2026-11-17
C20management claimmedium confidence
Management says Hers is progressing toward $1B of revenue this year, testosterone toward a $100M annual run-rate, and international toward a $1B run-rate in 2027.
against this

None of the three is a filed figure.

forwardwritten 2026-11-17
C18facthigh confidence
The FTC, with Utah and Los Angeles County, sued Hims & Hers in July 2026 over its subscription, cancellation and privacy practices; its motion to dismiss is set for 14 January 2027, and it accrued $62.5M for legal contingencies.
against this

The company says the claims are without merit and has moved to dismiss.

current state · 2026-09-30written 2026-11-17

What would change our view

  1. Unattractive→NeutralThe price falls back within 20% of fair value

    It needs:

    • ○The shares fall back within 20% above what we think the business is worth.about ≈$8.04 today, 57% below the last close
  2. Unattractive→AttractiveThe price falls 20% under fair value

    It needs:

    • ○The shares fall to 80% of what we think the business is worth.about ≈$6.70 today, 64% below the last close
  3. Unattractive→NeutralOperating profit returns with growth intact

    It needs all of:

    • ○Official operating profit passes 8% of sales over four quarters.checked at the next results, due by 22 Feb
    • ○Revenue growth over four quarters stays at 20% or more.checked at the next results, due by 22 Feb
We would also be wrong if
  • Subscribers fall for two more quarters after Lilly's drugs arrive.
  • The gross margin falls below 50% in a quarter of 2027.

What is coming

  • 14 January 2027 FTC case: hearing on the motion to dismiss: Whether the subscription and cancellation case proceeds, and what it could force on billing.
Every dated event ahead
  • 14 January 2027 FTC case: hearing on the motion to dismiss: Whether the subscription and cancellation case proceeds, and what it could force on billing.
  • 22 February 2027 Q4 2026 results and 2027 outlook: Whether subscribers grow again with Lilly's drugs on the platform, and what margin the 2027 guide implies.
  • 1 March 2027 2026 annual report: The year's GAAP loss, stock pay, any specialty revenue split and the Eucalyptus payments made in shares.
Since we wrote this
Written
17 Nov
Price the thesis read
$18.56
16 Nov
  • 17 NovThesis writtenUnattractive, high convictionA fast-growing online clinic, but on its best filed margin the price is about 439% of our value.

Sources 11

Where this came from

Sources - 11

Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.

  1. S01primarycompany filing2026-02-23
    business, specialties, subscribers, competition, regulation, risk factors, employees, providers, acquisitions and the five-year statements
    backsC01C02C10C11C15C16C23C32C35C38C39
  2. S02primarycompany release2026-02-23
    2025 revenue, adjusted EBITDA of $318.0M and the first 2026 outlook
    backsC10
  3. S03primarycompany release2026-11-09
    Q3 revenue by region, subscribers, revenue per subscriber, gross margin, net loss, adjusted EBITDA, cash flow, the balance sheet and the Q4 and 2026 outlook
    backsC03C04C05C09C12C35C37C40
  4. S04primarycompany filing2026-11-09
    statements, the weight-loss shift and its charges, the Eucalyptus and YourBio acquisitions, convertible notes, the receivables sale, legal proceedings and accruals, share counts
    backsC05C06C07C10C11C12C13C14C15C18C23C24C37
  5. S05primarytranscript2026-11-09
    management's strategy, the Lilly and Novo assortment, testosterone and peptides, the AI experience, marketing pacing, international and the subscriber outlook
    In health care, whoever owns the customer relationship wins.
    backsC03C07C09C20C21C22C38
  6. S06primarycompany filing2026-04-28
    the chief executive's voting control, ownership by directors and officers, and how pay is earned
    backsC29C30C31
  7. S07primarycompany release2026-11-06
    the supplier's own terms: Zepbound and Foundayo at Lilly's self-pay prices, and Hims & Hers' commitment not to offer compounded copies of Lilly's drugs
    eligible patients ... will access the same self-pay prices available to any patient without leaving the Hims & Hers platform
    backsC08
  8. S08primaryindustry data2025-11-14
    how many US adults take a GLP-1 drug, where they get it and who pays
    About one in eight adults (12%) say that they are currently taking a GLP-1 drug
    backsC19
  9. S09primarycompany filing2026-03-10
    a listed rival's own description of the same direct-to-patient telehealth business
    backsC17
  10. S10secondaryvendor data2026-11-17
    the close, the one-year price move split into sales and multiple, analyst ratings, the analysts' revenue and profit forecasts, earnings surprises and insider transaction counts
    backsC24C25C26C33C36
  11. S11primaryregulator2026-10-30
    shares sold short and days to cover
    settlement_date 2026-10-30 shares_short 51657110 days_to_cover 5.84
    backsC34
Rendered from content/HIMS/thesis.json · thesis reviewed 2026-11-17. This page explains a company; it does not say what to pay, when to buy or how much.